account_balance
Investment manager · 13F filer · SEC CIK 1917529
Atlas Venture Life Science Advisors, LLC
Reported value$631Mas of Sep 30, 2026
Positions9 2 new, 0 sold out
Top 10 weight100.0%KYMR alone is 50%
FiledNov 1041 days after quarter end
Portfolio · as of Sep 30, 2026
Where the money is
New or addedTrimmedHeld
This fund reports 9 stocks.
KYMRKymera Therapeutics, Inc.
50.4%
IRONDisc Medicine, Inc.
14.4%Trimmed −9%
OBXObsidian Therapeutics, Inc.
9.8%New
KLRAKailera Therapeutics, Inc.
9.4%
DYNDyne Therapeutics, Inc.
8.8%Trimmed −49%
QTTBQ32 Bio, Inc.
3.6%
SIONSionna Therapeutics, Inc.
2.5%
KRRO1.2%KYMRKymera Therapeutics, Inc.
50.4%
IRONDisc Medicine, Inc.
14.4%Trimmed −9%
OBXObsidian Therapeutics, Inc.
9.8%New
KLRA9.4%DYN8.8%QTTB3.6%SION2.5%Box size is the share of the fund. 13F only covers US-listed stocks, so foreign holdings and short positions are missing.
Show the top 9 as a list
KYMR Kymera Therapeutics, Inc. 50.4% HeldIRON Disc Medicine, Inc. 14.4% Trimmed −9%OBX Obsidian Therapeutics, Inc. 9.8% NewKLRA Kailera Therapeutics, Inc. 9.4% HeldDYN Dyne Therapeutics, Inc. 8.8% Trimmed −49%QTTB Q32 Bio, Inc. 3.6% HeldSION Sionna Therapeutics, Inc. 2.5% HeldKRRO Korro Bio, Inc. 1.2% Trimmed −20%ODTX Odyssey Therapeutics, Inc. 0.0% New
What changed